OAM
PCRX icon

Oxford Asset Management’s Pacira BioSciences PCRX Stock Holding History

Oxford Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,684
Closed -$801K – 983
2019
Q4 		$801K Sell
17,684
-19,993
-53% -$849K 0.02% 990
2019
Q3 		$1.43M Buy
37,677
+6,165
+20% +$246K 0.03% 739
2019
Q2 		$1.37M Buy
31,512
+4,261
+16% +$181K 0.03% 824
2019
Q1 		$1.04M Sell
27,251
-27,255
-50% -$1.06M 0.02% 915
2018
Q4 		$2.35M Buy
54,506
+19,085
+54% +$891K 0.06% 388
2018
Q3 		$1.74M Sell
35,421
-14,503
-29% -$627K 0.04% 742
2018
Q2 		$1.55M Buy
49,924
+32,271
+183% +$1.11M 0.03% 814
2018
Q1 		$550K Sell
17,653
-81,212
-82% -$2.89M 0.01% 1203
2017
Q4 		$4.49M Buy
98,865
+33,624
+52% +$1.33M 0.1% 252
2017
Q3 		$2.52M Buy
65,241
+3,933
+6% +$158K 0.05% 503
2017
Q2 		$2.92M Buy
61,308
+44,610
+267% +$2.07M 0.06% 414
2017
Q1 		$761K Buy
+16,698
New +$722K 0.02% 914
2016
Q3 		– Sell
-29,061
Closed -$980K – 832
2016
Q2 		$980K Buy
+29,061
New +$1.43M 0.03% 489
2016
Q1 		– Sell
-170,199
Closed -$13.2M – 868
2015
Q4 		$13.2M Buy
170,199
+141,695
+497% +$8.02M 0.31% 54
2015
Q3 		$1.17M Sell
28,504
-275
-1% -$16.8K 0.04% 381
2015
Q2 		$2.04M Sell
28,779
-68,112
-70% -$5.36M 0.06% 342
2015
Q1 		$8.61M Sell
96,891
-26,408
-21% -$2.68M 0.22% 100
2014
Q4 		$11.1M Sell
123,299
-32,014
-21% -$3.03M 0.24% 67
2014
Q3 		$15.4M Buy
155,313
+7,889
+5% +$767K 0.35% 45
2014
Q2 		$13.5M Buy
+147,424
New +$11.2M 0.44% 38
2013
Q4 		– Sell
-46,071
Closed -$2.22M – 769
2013
Q3 		$2.22M Sell
46,071
-80,051
-63% -$2.92M 0.05% 428
2013
Q2 		$3.66M Buy
+126,122
New +$3.65M 0.1% 337

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Oxford Asset Management's PCRX Position: Q1 2020 in Review

Oxford Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 17,684 shares — an estimated $801K sold.

Oxford Asset Management first reported a position in PCRX in Q2 2013 and held it in 22 quarters. The position peaked at $15.4M in Q3 2014. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

  • Oxford Asset Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 17,684 Pacira BioSciences shares in Q1 2020, an estimated $801K.
  • Oxford Asset Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 22 quarters.
  • Oxford Asset Management's Pacira BioSciences position peaked at $15.4M in Q3 2014.
  • 226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.